Comparing ranibizumab 0.5 mg versus sham or PTD treatment , respectively : 39.9 % versus 29.1 % and 10.9 % versus 5.1 % had maximum preinjection IOPs of 21 mmHg or more or 25 mmHg or more , respectively ; 44.1 % versus 29.9 % and 24.2 % versus 13.6 % had IOP increases from baseline of 6 mmHg or more or 8 mmHg or more , respectively ; 26.1 % versus 13.6 % and 16.8 % versus 9.0 % had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more , respectively , with a concurrent IOP of 21 mmHg or more ; 9.6 % versus 3.7 % and 7.5 % versus 2.4 % had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more , respectively , with a concurrent IOP of 25 mmHg or more .